utility of tetracycline derivatives in treatment of cns toxoplasmosis.

NLM AIDSLINE Utility of tetracycline derivatives in treatment of CNS toxoplasmosis. Bockman KW; Gathe J Jr; Stool E; Frazier R; Najjar A; Piot D; Park Plaza
November 30, 1993

Int Conf AIDS. 1993 Jun 6-11;9(1):373 (abstract no. PO-B10-1427). Unique OBJECTIVE: To describe the efficacy of tetracycline derivative alone or in combination with pyrimethamine (P) in therapy of CNS toxoplasmosis. METHODS: Prospective evaluation of 7 patients with biopsy proven (4) or presumed (3) CNS toxoplasmosis. Responses to therapy is defined as complete alleviation of symptoms as well as shrinkage of the CNS lesion by at least 75%. RESULTS: All patients responded to initial treatment-[doxycycline alone (1) 4 mg/kg/day, minocycline alone (3) 4 mg/kg/day, or (P)/minocycline 1)]. The 2 other patients who had not responded and/or tolerated standard toxoplasma medications had a complete response to either doxycycline alone or (P)/minocycline. Three patients died of unrelated AIDS complications; 2 at autopsy had no evidence of CNS or systemic toxoplasmosis, the other had a negative premorbid MRI of the head. Four patients are alive and asymptomatic on P)/minocycline (2) or minocycline alone (2). The maximum time of prospective follow-up to date is 15 months. CONCLUSIONS: 1.) Tetracycline derivatives, particularly minocycline are efficacious in therapy of CNS toxoplasmosis either alone or in combination with (P). 2.) Efficacy was also seen in patients intolerant or unresponsive to standard therapies. 3.) No significant toxicity was seen. 4.) While controlled studies will be necessary to establish superiority as compared to standard therapies, the safety and efficacy of minocycline compels us to begin a prophylactic study with this agent for prevention of symptomatic toxoplasmosis. AIDS-Related Opportunistic Infections/DRUG THERAPY Central Nervous System Diseases/DRUG THERAPY Doxycycline/THERAPEUTIC USE Minocycline/THERAPEUTIC USE Toxoplasmosis/DRUG THERAPY Toxoplasmosis, Cerebral/DRUG THERAPY

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV Viet Nam: South-South learning helps prepare for sustainable provision of AIDS treatment China and Africa Discuss Health Treatment Problems Simpler ARV treatment begins in Eastern Cape AFRICA: Less-Used HIV Treatment for African Children More Effective CANADA: Drug-Resistant Gonorrhea Prompts New Treatment Guidelines in Ont. Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies Less-Used HIV Treatment for African Children More Effective The Next Step in Drug Treatment Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 Percent of Patients with Hepatitis C in Phase 3 Pivotal Trial AHF Applauds WHO Decision to Initiate HIV Treatment Earlier
Information in this article was accurate in November 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.